Skip to main content

Table 4 Comparison of exploratory pharmacodynamic parameter between treatment groups at week 12

From: Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

 

ITT analysis

PP analysis

Test (n = 27)

Reference (n = 13)

Test (n = 27)

Reference (n = 11)

Interleukin-6

 Change from baseline at week 12

−8.2 (15.97)*

−10.8 (19.86)#

−8.2 (15.97)*

−13.5 (20.44)$

 MD (±SE)

2.60 (5.84)

5.30 (6.20)

 95% CI

(−9.2,14.4)

(−7.3, 17.9)

p value

0.878

0.436

  1. p values were obtained using paired t-test; *p = 0.012 vs. baseline; #p = 0.0727 vs. baseline; $p = 0.0525 vs. baseline
  2. CI Confidence interval, ITT Intention-to-treat, PP, Per protocol, MD Mean difference, SE Standard error